Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propazine SCHEMBL67521 | 0.86 | GAA (1.00) | GAATDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL1923400 | 0.86 | GAA (0.90) | GAATDP1POLBALDH1A1L3MBTL1 | |
| Propazine SCHEMBL8539531 | 0.86 | GAA (1.00) | GAATDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL9970686 | 0.84 | GAA (0.61) | GAATDP1ALDH1A1MAPK1HTT | |
| SCHEMBL15599529 | 0.84 | GAA (0.54) | GAATDP1ALDH1A1MAPK1HTT | |
| SCHEMBL10078277 | 0.83 | GAA (0.52) | GAATDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL2684956 | 0.78 | GAA (0.83) | GAATDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL15102677 | 0.77 | GAA (0.72) | GAATDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL1425222 | 0.77 | GAA (0.72) | GAATDP1POLBALDH1A1L3MBTL1 | |
| SCHEMBL2492890 | 0.77 | GAA (0.79) | GAATDP1POLBALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| WO-2019047909-A1 | CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666661-B2 | Methods and compounds for targeted autophagy | ATG7, BECN1, SQSTM1 | GAA 148/4885TDP1 2216/4885POLB 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.